GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. More Details
Reasonable growth potential with weak fundamentals.
Share Price & News
How has GeNeuro's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GNRO is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: GNRO's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: GNRO underperformed the French Biotechs industry which returned 37.8% over the past year.
Return vs Market: GNRO underperformed the French Market which returned -1.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is GeNeuro's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StAnalysts Expect Breakeven For GeNeuro SA (EPA:GNRO) Before Long
1 month ago | Simply Wall StOur View On GeNeuro's (EPA:GNRO) CEO Pay
3 months ago | Simply Wall StGeNeuro SA (EPA:GNRO): When Will It Breakeven?
Is GeNeuro undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether GeNeuro is trading at an attractive price based on the cash flow it is expected to produce in the future. But as GeNeuro has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at GeNeuro's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through GeNeuro regulatory filings.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
How is GeNeuro forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GNRO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).
Earnings vs Market: GNRO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: GNRO's is expected to become profitable in the next 3 years.
Revenue vs Market: GNRO is forecast to have no revenue next year.
High Growth Revenue: GNRO is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GNRO's Return on Equity is forecast to be very high in 3 years time (103.8%).
How has GeNeuro performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GNRO is currently unprofitable.
Growing Profit Margin: GNRO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GNRO is unprofitable, and losses have increased over the past 5 years at a rate of 9.5% per year.
Accelerating Growth: Unable to compare GNRO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GNRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11.2%).
Return on Equity
High ROE: GNRO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is GeNeuro's financial position?
Financial Position Analysis
Short Term Liabilities: GNRO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: GNRO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: GNRO has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: GNRO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if GNRO has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if GNRO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is GeNeuro current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GNRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GNRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GNRO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GNRO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GNRO's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jesus Martin-Garcia (58 yo)
Mr. Jesús Martin-Garcia is the Founding Partner, General Partner, and Director of Eclosion SA. He serves at GeNeuro SA as the Chairman of the Board since February 06, 2006 and Chief Executive Officer since...
CEO Compensation Analysis
Compensation vs Market: Jesus's total compensation ($USD878.77K) is above average for companies of similar size in the French market ($USD261.84K).
Compensation vs Earnings: Jesus's compensation has increased whilst the company is unprofitable.
|Chairman & CEO||4.83yrs||€735.00k||no data|
|Chief Financial Officer||5yrs||no data||no data|
|Chief Scientific Officer||no data||no data||no data|
|Chief Medical Officer||0.50yr||no data||no data|
|Chief Development Officer||0.17yr||no data||no data|
Experienced Management: GNRO's management team is considered experienced (2.7 years average tenure).
|Chairman & CEO||4.83yrs||€735.00k||no data|
|Independent Director||12.33yrs||€23.10k||no data|
|Independent Director||5.67yrs||€32.30k||no data|
|Independent Director||5.33yrs||€23.50k||no data|
|Independent Director||5yrs||no data||no data|
|Director||5yrs||no data||no data|
|Director||0.17yr||no data||no data|
Experienced Board: GNRO's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.5%.
GeNeuro SA's company bio, employee growth, exchange listings and data sources
- Name: GeNeuro SA
- Ticker: GNRO
- Exchange: ENXTPA
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €62.043m
- Shares outstanding: 20.48m
- Website: https://www.geneuro.ch
Number of Employees
- GeNeuro SA
- 3 chemin du Pré-Fleuri
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GNRO||ENXTPA (Euronext Paris)||Yes||Class C Common Shares||FR||EUR||Apr 2016|
|GEM||DB (Deutsche Boerse AG)||Yes||Class C Common Shares||DE||EUR||Apr 2016|
|GNROP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Class C Common Shares||GB||EUR||Apr 2016|
|0RHK||LSE (London Stock Exchange)||Yes||Class C Common Shares||GB||EUR||Apr 2016|
|GNRR.F||OTCPK (Pink Sheets LLC)||Yes||Class C Common Shares||US||USD||Apr 2016|
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. Its lead therapeutic candidate is temelimab, a monoclonal antibody, wh...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/28 19:21|
|End of Day Share Price||2020/11/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.